---
document_datetime: 2025-12-29 14:20:58
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-disoproxil-krka-dd.html
document_name: emtricitabine-tenofovir-disoproxil-krka-dd.html
version: success
processing_time: 0.1267247
conversion_datetime: 2025-12-29 23:30:51.85822
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Emtricitabine/Tenofovir disoproxil Krka d.d.

[RSS](/en/individual-human-medicine.xml/66874)

##### Authorised

This medicine is authorised for use in the European Union

emtricitabine / tenofovir disoproxil Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Emtricitabine/Tenofovir disoproxil Krka d.d.](#news-on)
- [More information on Emtricitabine/tenofovir disoproxil Krka d.d.](#more-information-on-emtricitabinetenofovir-disoproxil-krka-dd-1463)
- [Related information](#related-information-807)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Emtricitabine/Tenofovir disoproxil Krka d.d. is an HIV medicine that is used in combination with at least one other HIV medicine to treat adults infected with human immunodeficiency virus type 1 (HIV 1), a virus that causes acquired immune deficiency syndrome (AIDS). In addition, it may be used in adolescents who are resistant to first-line treatments or who cannot take them because of side effects.

Emtricitabine/Tenofovir disoproxil Krka d.d contains two active substances, emtricitabine and tenofovir disoproxil. It is a 'generic medicine'. This means that it contains the same active substances and works in the same way as a 'reference medicine' already authorised in the EU called Truvada.

Expand section

Collapse section

## How is Emtricitabine/Tenofovir disoproxil Krka d.d. used?

Emtricitabine/Tenofovir disoproxil Krka d.d. can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection.

Emtricitabine/Tenofovir disoproxil Krka d.d. is available as tablets (200 mg emtricitabine and 245 mg tenofovir disoproxil). The recommended dose is one tablet once a day, preferably taken with food. If patients need to stop taking emtricitabine or tenofovir, or need to take different doses, they will need to take medicines containing emtricitabine or tenofovir disoproxil separately.

For more informationabout using Emtricitabine/Tenofovir disoproxil Krka d.d., see the package leaflet or contact your doctor or pharmacist.

## How does Emtricitabine/Tenofovir disoproxil Krka d.d. work?

Emtricitabine/Tenofovir disoproxil Krka d.d. contains two active substances: emtricitabine, which is a nucleoside reverse transcriptase inhibitor; and tenofovir disoproxil, which is a 'prodrug' of tenofovir. This means that it is converted into tenofovir in the body. Tenofovir is a nucleotide reverse transcriptase inhibitor. Both emtricitabine and tenofovir work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to reproduce itself in the cells it has infected.

Emtricitabine/Tenofovir disoproxil Krka d.d., taken in combination with at least one other antiviral medicine, reduces the amount of HIV in the blood and keeps it at a low level. Emtricitabine/Tenofovir disoproxil Krka d.d. does not cure HIV infection or AIDS, but it holds off the damage to the immune system and the development of infections and diseases associated with AIDS.

## How has Emtricitabine/Tenofovir disoproxil Krka d.d. been studied?

Studies on the benefits and risks of the active substances in the authorised use have already been carried out with the reference medicine, Truvada, and do not need to be repeated for Emtricitabine/Tenofovir disoproxil Krka d.d.

As for every medicine, the company provided studies on the quality of Emtricitabine/Tenofovir disoproxil Krka d.d. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substances in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Emtricitabine/Tenofovir disoproxil Krka d.d.?

Because Emtricitabine/Tenofovir disoproxil Krka d.d. is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Emtricitabine/Tenofovir disoproxil Krka d.d. authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Emtricitabine/Tenofovir disoproxil Krka d.d. has been shown to have comparable quality and to be bioequivalent to Truvada. Therefore, the Agency's view was that, as for Truvada, the benefit of Emtricitabine/Tenofovir disoproxil Krka d.d. outweighs the identified risk and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Emtricitabine/Tenofovir disoproxil Krka d.d.?

The company that markets Emtricitabine/Tenofovir disoproxil Krka d.d. will provide an information pack to doctors which covers the potential harmful effects of Emtricitabine/Tenofovir disoproxil Krka d.d. on kidney function in adults and children.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Emtricitabine/Tenofovir disoproxil Krka d.d. have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Emtricitabine/Tenofovir disoproxil Krka d.d. are continuously monitored. Side effects reported with Emtricitabine/Tenofovir disoproxil Krka are carefully evaluated and any necessary action taken to protect patients.

## Other information about Emtricitabine/Tenofovir disoproxil Krka d.d.

The European Commission granted a marketing authorisation valid throughout the EU for Emtricitabine/Tenofovir disoproxil Krka d.d. on 28 April 2017.

Emtricitabine/Tenofovir disoproxil Krka d.d. : EPAR - Medicine overview

Reference Number: EMA/13195/2019

English (EN) (128.49 KB - PDF)

**First published:** 09/06/2017

**Last updated:** 26/09/2019

[View](/en/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-731)

български (BG) (118.37 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/bg/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_bg.pdf)

español (ES) (88.85 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/es/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_es.pdf)

čeština (CS) (113.14 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/cs/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_cs.pdf)

dansk (DA) (88.37 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/da/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_da.pdf)

Deutsch (DE) (89.87 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/de/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_de.pdf)

eesti keel (ET) (87.91 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/et/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_et.pdf)

ελληνικά (EL) (129.87 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/el/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_el.pdf)

français (FR) (89.58 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/fr/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_fr.pdf)

hrvatski (HR) (107.41 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/hr/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_hr.pdf)

italiano (IT) (87.91 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/it/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (119.34 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/lv/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (111.04 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/lt/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_lt.pdf)

magyar (HU) (108.19 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/hu/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_hu.pdf)

Malti (MT) (121.52 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/mt/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_mt.pdf)

Nederlands (NL) (89.15 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/nl/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_nl.pdf)

polski (PL) (115.28 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/pl/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_pl.pdf)

português (PT) (88.98 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/pt/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_pt.pdf)

română (RO) (120.93 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/ro/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_ro.pdf)

slovenčina (SK) (112.46 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/sk/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_sk.pdf)

slovenščina (SL) (106.45 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/sl/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_sl.pdf)

Suomi (FI) (88.35 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/fi/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_fi.pdf)

svenska (SV) (88.1 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

26/09/2019

[View](/sv/documents/overview/emtricitabinetenofovir-disoproxil-krka-dd-epar-medicine-overview_sv.pdf)

## Product information

Emtricitabine/Tenofovir disoproxil Krka d.d. : EPAR - Product Information

English (EN) (307.37 KB - PDF)

**First published:** 09/06/2017

**Last updated:** 05/02/2025

[View](/en/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-681)

български (BG) (356.12 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/bg/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_bg.pdf)

español (ES) (320.61 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/es/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_es.pdf)

čeština (CS) (330.03 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/cs/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_cs.pdf)

dansk (DA) (343.43 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/da/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_da.pdf)

Deutsch (DE) (362.55 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/de/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_de.pdf)

eesti keel (ET) (314.24 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/et/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_et.pdf)

ελληνικά (EL) (370.16 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/el/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_el.pdf)

français (FR) (342.95 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/fr/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_fr.pdf)

hrvatski (HR) (308.42 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/hr/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_hr.pdf)

íslenska (IS) (309.03 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/is/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_is.pdf)

italiano (IT) (312.22 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/it/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_it.pdf)

latviešu valoda (LV) (323.82 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/lv/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_lv.pdf)

lietuvių kalba (LT) (332.48 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/lt/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_lt.pdf)

magyar (HU) (354.16 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/hu/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_hu.pdf)

Malti (MT) (377.79 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/mt/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_mt.pdf)

Nederlands (NL) (312.67 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/nl/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_nl.pdf)

norsk (NO) (330.04 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/no/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_no.pdf)

polski (PL) (355.19 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/pl/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_pl.pdf)

português (PT) (321.76 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/pt/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_pt.pdf)

română (RO) (343.55 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/ro/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_ro.pdf)

slovenčina (SK) (341.34 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/sk/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_sk.pdf)

slovenščina (SL) (324.83 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/sl/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_sl.pdf)

Suomi (FI) (319.1 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/fi/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_fi.pdf)

svenska (SV) (330.75 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

05/02/2025

[View](/sv/documents/product-information/emtricitabine-tenofovir-disoproxil-krka-dd-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000242563 31/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Emtricitabine/Tenofovir disoproxil Krka d.d. : EPAR - All Authorised presentations

English (EN) (36.32 KB - PDF)

**First published:** 09/06/2017

**Last updated:** 04/12/2020

[View](/en/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-632)

български (BG) (45.78 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/bg/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_bg.pdf)

español (ES) (31.73 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/es/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_es.pdf)

čeština (CS) (37.96 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/cs/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (36.76 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/da/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (37.59 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/de/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (37.27 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/et/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (41.1 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/el/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_el.pdf)

français (FR) (29.93 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/fr/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (37.61 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/hr/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (31.21 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/is/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_is.pdf)

italiano (IT) (36.7 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/it/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (31.18 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/lv/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (38.41 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/lt/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (37.54 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/hu/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (39.37 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/mt/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (29.21 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/nl/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (36.79 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/no/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_no.pdf)

polski (PL) (37.96 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/pl/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_pl.pdf)

português (PT) (36.28 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/pt/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_pt.pdf)

română (RO) (37.69 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/ro/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (31.53 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/sk/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (29.58 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/sl/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (35.41 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/fi/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (35.83 KB - PDF)

**First published:**

09/06/2017

**Last updated:**

04/12/2020

[View](/sv/documents/all-authorised-presentations/emtricitabinetenofovir-disoproxil-krka-dd-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Emtricitabine/Tenofovir disoproxil Krka d.d. Active substance

- emtricitabine
- tenofovir disoproxil succinate

International non-proprietary name (INN) or common name

- emtricitabine
- tenofovir disoproxil

Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AR03

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Emtricitabine/Tenofovir disoproxil Krka d.d. is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.

Emtricitabine/Tenofovir disoproxil Krka d.d. is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to &lt; 18 years.

## Authorisation details

EMA product number EMEA/H/C/004686

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

KRKA, d.d., Novo mesto

Smarjeska cesta 6

Opinion adopted 23/02/2017 Marketing authorisation issued 28/04/2017 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Emtricitabine/Tenofovir disoproxil Krka d.d. : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (143.71 KB - PDF)

**First published:** 12/07/2024

**Last updated:** 05/02/2025

[View](/en/documents/procedural-steps-after/emtricitabine-tenofovir-disoproxil-krka-dd-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Emtricitabine/Tenofovir disoproxil Krka d.d. : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (182.34 KB - PDF)

**First published:** 12/07/2017

**Last updated:** 02/07/2024

[View](/en/documents/procedural-steps-after/emtricitabine-tenofovir-disoproxil-krka-dd-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Emtricitabine/Tenofovir disoproxil Krka d.d. : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/236203/2017

English (EN) (320.69 KB - PDF)

**First published:** 09/06/2017

**Last updated:** 09/06/2017

[View](/en/documents/assessment-report/emtricitabinetenofovir-disoproxil-krka-dd-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Emtricitabine/Tenofovir disoproxil Krka d.d.

Adopted

Reference Number: EMA/CHMP/75449/2017

English (EN) (69.09 KB - PDF)

**First published:** 24/02/2017

**Last updated:** 24/02/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-emtricitabinetenofovir-disoproxil-krka-dd_en.pdf)

#### News on Emtricitabine/Tenofovir disoproxil Krka d.d.

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 February 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2017) 24/02/2017

#### More information on Emtricitabine/tenofovir disoproxil Krka d.d.

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0046860000) (initial marketing authorisation)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 05/02/2025

## Share this page

[Back to top](#main-content)